Delcath Systems (DCTH) Reports First CHEMOSAT Treatment with Hemofiltration Cartridge
Tweet
Share
E-mailGet Alerts DCTH Hot Sheet
Join SI Premium – FREE
Delcath Systems, Inc. (Nasdaq: DCTH) reports that the first treatment using the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System has been performed at the European Institute of Oncology (Instituto Europeo di Oncologia – IEO), a premier cancer treatment and research center in Milan.
A patient was treated for inoperable liver-dominant metastases from ocular melanoma, a case that represents the first use of the second generation hemofiltration cartridge in a clinical setting. The IEO treatment team reports the patient is doing well and has not suffered any procedure-related complications.
A patient was treated for inoperable liver-dominant metastases from ocular melanoma, a case that represents the first use of the second generation hemofiltration cartridge in a clinical setting. The IEO treatment team reports the patient is doing well and has not suffered any procedure-related complications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
